Executive Moves | Healthcare | BioTuesdays by Kilmer Lucas IR

Executive Moves

Evotec appoints Dr. Ashiq H. Khan as CCO

Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT) has appointed Dr. Ashiq H. Khan as EVP global head, chief commercial officer (CCO). Dr. Khan brings more than 15 years of international leadership experience in...

April 1, 2026

Executive Moves

Dr. Raj S. Pruthi joins PreveCeutical’s BOD

PreveCeutical Medical (CSE: PREV; OTCQB: PRVCF; FSE: 18H0) has appointed Raj S. Pruthi, MD, MHA, FACS, to its board of directors (BOD). Dr. Pruthi currently serves as CMO of Relmada Therapeutics. An accomplished...

March 30, 2026

Executive Moves

Wang Haijiao joins Fangzhou as CEO

Fangzhou (HKEX: 06086) has announced the appointment of Wang Haijiao as chief executive officer (CEO) and executive director, effective today. Mr. Wang’s nearly 20 years of extensive healthcare industry experience in...

March 26, 2026

Executive Moves

Evolent names Archie Mayani as CPO

Evolent Health (NYSE: EVH) has announced the appointment of healthcare technology leader and AI innovator, Archie Mayani, as chief product officer (CPO). Ms. Mayani brings more than two decades of leadership experience...

March 19, 2026

Executive Moves

MindMaze appoints Zach Henderson as CEO

MindMaze Therapeutics (SIX: MMTX) has announced the appointment of health tech veteran Zach Henderson as chief executive officer (CEO). With more than 30 years of experience scaling healthcare technology platforms and...

March 12, 2026

Executive Moves

Dr. Torsten Malmström joins Spago as director CMC & supply

Spago Nanomedical (STO:SPAGO.ST; FRA:7UX.F) has announced that Torsten Malmström, PhD, has been appointed director of chemistry, manufacturing, and controls (CMC) and joins the company’s management team. Dr. Malmström...

March 11, 2026

Executive Moves

Alterity names Dr. Daniel O. Claassen chief medical advisor

Alterity Therapeutics (ASX: ATH; NASDAQ: ATHE) has announced that Daniel O. Claassen, MD, PhD, has been appointed chief medical advisor. In addition to this role, Dr. Claassen will retain his academic appointment as...

March 4, 2026

Executive Moves

Prof. Joshua C. Brown joins NRx as CMO

NRx Pharmaceuticals (NASDAQ: NRXP) has announced the appointment of Prof. Joshua C. Brown, MD, PhD, as chief medical officer. Prof. Brown, a pioneer in understanding the biologic effect of Transcranial Magnetic...

March 2, 2026

Executive Moves

Foghorn appoints Ryan Maynard as CFO

Foghorn Therapeutics (NASDAQ: FHTX) has announced that Ryan Maynard will join the company as chief financial officer (CFO) effective today. Mr. Maynard brings more than 25 years of executive experience driving financial...

February 23, 2026

Executive Moves

Drs. Mark Eisner and Ajay Nirula join Zura Bio’s BOD

Zura Bio (NASDAQ: ZURA) has announced the appointments of Mark Eisner, MD, PhD, and Ajay Nirula, MD, PhD, to its board of directors (BOD), effective February 21, 2026. Neil Graham, MBBS, MD, MPH, stepped down from the...

February 23, 2026

Executive Moves

Veteran investment banker Jason Arnold joins Piper Sandler

Seasoned investment banker Jason Arnold has joined Piper Sandler as a managing director in the healthcare investment banking group. He will be advising life science tools and diagnostic companies on mergers and...

February 23, 2026

Executive Moves

ROTH expands healthcare team across banking, sales, research

Investment bank ROTH Capital Partners LLC has further expanded its healthcare platform across investment banking, institutional sales, and equity research with the addition of Jack Terranova, Noah Huehnergarth, and Max...

February 13, 2026

Executive Moves

Rita Johnson-Greene joins Ocugen as CFO

Ocugen (NASDAQ: OCGN) has appointed Rita Johnson-Greene as chief financial officer (CFO). Ms. Johnson-Greene brings more than 20 years of healthcare experience to the role. Most recently, she served as chief operating...

February 9, 2026

Executive Moves

LeonaBio appoints industry veteran Mark F. Kubic as CBO

LeonaBio (NASDAQ: LONA) has appointed Mark F. Kubic as chief business officer (CBO) to lead the company’s business development strategy and execution. Mr. Kubik served as a strategic consultant to LeonaBio and played a...

February 3, 2026

Executive Moves

STAAR appoints Warren Foust and Deborah Andrews as interim co-CEOs

STAAR Surgical (NASDAQ: STAA) has announced that its board of directors has appointed Warren Foust, president and CEO, and Deborah Andrews, CFO, as interim co-CEOs, effective yesterday. According to STAAR, the board’s...

February 2, 2026

Executive Moves

Carisa Schultz joins Nuwellis as CFO

Nuwellis (NASDAQ: NUWE) has announced the appointment of Carisa Schultz as chief financial officer (CFO), effective February 2, 2026. Ms. Schultz brings extensive healthcare and public company finance leadership...

January 30, 2026

Executive Moves

AIML names Dr. Paul Dorian MIA and head of medical advisory board

AIML Innovations (CSE: AIML; OTCQB: AIMLF; FWB: 42FB) has announced the appointment of Paul Dorian, MD, MSc, as its medical innovation architect (MIA) and head of the company’s medical advisory board, effective...

January 28, 2026

Executive Moves

Rani appoints Dr. Alireza Javadi as CTO

Rani Therapeutics (NASDAQ: RANI) has announced the promotion of Alireza Javadi, PhD, to chief technical officer. Prior to the promotion to CTO, Dr. Javadi served as Rani’s VP, technical operations, where he was...

January 28, 2026

Executive Moves

Zura names Dr. Sandeep Kulkarni as CEO

Zura Bio (NASDAQ: ZURA) has appointed Sandeep Kulkarni, MD, as chief executive officer (CEO), effective today. Dr. Kulkarni will continue to serve as a director of Zura. He succeeds Kim Davis, JD, who has served as...

January 21, 2026

Executive Moves

MediPharm appoints Greg Hunter interim CEO

MediPharm Labs (TSX: LABS; OTCQB: MEDIF; FSE: MLZ) has announced that its CEO, David Pidduck, will step down from his role as of January 23, 2026, and that Greg Hunter, the company’s CFO, has been appointed interim CEO...

January 19, 2026

Executive Moves

Arch names Dr. Patrick Vink as chairman of BOD

Arch Biopartners (TSXV: ARCH; OTCQB: ACHFF) has announced the appointment of Dr. Patrick Vink as chairman of the company’s board of directors (BOD), effective January 15, 2026. Dr. Vink, MD, MBA, has been an advisor to...

January 16, 2026

Executive Moves

Oncolytics names John McAdory EVP strategy and operations; Yujun Wu VP biostatistics

Oncolytics Biotech (NASDAQ: ONCY) has announced the appointments of John McAdory as executive vice president (EVP), strategy and operations, and Yujun Wu as vice president (VP), head of biostatistics. According to...

January 14, 2026

Subscribe